A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity.
about
Using nonhuman primates to model HIV transmissionSelective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispeciesBottlenecks in HIV-1 transmission: insights from the study of founder virusesDifferences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder VirusSurvivors Remorse: antibody-mediated protection against HIV-1.Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.Phenotypic properties of transmitted founder HIV-1Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression.Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7Application of a case-control study design to investigate genotypic signatures of HIV-1 transmission.Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope.Differentiating founder and chronic HIV envelope sequences.HIV transmissionPostnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variantsAntigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairsInfection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections.Transmission of Multiple HIV-1 Subtype C Transmitted/founder Viruses into the Same Recipients Was not Determined by Modest Phenotypic Differences.Recent advances in research of HIV infection: implications of viral and host genetics on treatment and prevention.The virus-receptor interaction in the replication of feline immunodeficiency virus (FIV).Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide.Guanylate binding protein 5: Impairing virion infectivity by targeting retroviral envelope glycoproteins.The HIV-1 transmission bottleneck.Conference report: "Functional Glycomics in HIV Type 1 Vaccine Design" workshop report, Bethesda, Maryland, April 30-May 1, 2012.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations.Signal peptide of HIV envelope protein impacts glycosylation and antigenicity of gp120.Advances in HIV-1 Vaccine Development.
P2860
Q26861425-DCE82EF4-806B-43F6-8EBD-F6DADAD8800BQ27318192-F23DDD7D-AE56-4CF0-85D3-944322E488FFQ28082862-974AE75C-1304-4B76-9DAC-8DF3FAD039B7Q28551914-2B57B0E1-EA96-4E1D-9BEB-4CBF243B8CF5Q30238730-18F57718-4E7B-48A9-896D-DAD0A92A7DF9Q30378764-4F146FDC-283F-4B09-9B5B-0B5C402BBF43Q34336058-B3FFBE22-D78C-4BC0-BD21-3F5B916A7111Q34593647-CCB046CE-C023-4161-8321-EC15B21FDABAQ34806205-49E3DE69-7D65-4728-AF87-DCD3BC2A3BB1Q36000722-DAA10F38-9045-4FD3-AFD2-1906D0498DCFQ36164165-DC9189AC-B807-4DE0-A14B-7611CFFED1DEQ36246315-828AADAE-942D-4514-9B60-E4F3D6E0FDA3Q36277153-DBC6569B-8F4C-4E13-A1FD-0456288693E1Q36526615-0498FC87-F982-42C4-B442-6E8AA88C94B8Q36588632-D1FCD719-D620-4404-98E9-ED4617A9EAF8Q36760169-37CF49AD-7166-44F0-84CE-FF2696FA8F13Q36978861-75DA639A-5DC6-4E1D-8CEC-C2D0A5803423Q37233074-01BD92CB-27AC-4902-8E36-99486A4C07AAQ37442592-675C7D02-0032-4570-AB61-6E6F0642F485Q37464540-5F4CC2B0-5C6D-4E77-82C1-7DDAD1EE5CACQ38095239-779DD081-91B9-4BD2-804A-8464F5108A71Q38132942-06CE51F6-311A-49E6-9318-BE7F5E0976D6Q40104259-A28C2C75-116F-4EFA-89D4-43E18669D3CAQ40640876-4487F7FF-96FF-45D5-B503-B5ADAA71DD16Q42314454-DBA45952-5293-4468-99DD-D2EA7800435EQ42933039-0AFDC535-5E77-407B-B34D-59C45DBBECADQ47110966-A3E20D1C-E53E-48E2-9270-B994BFF87BD4Q47548907-84F223A0-59D3-4348-9215-B9423E7CFC97Q49790276-870722F7-8C8C-4B0B-BD05-D7899F50FC53Q52609661-474DCAC7-7AB8-4FAA-8681-20952F0167B0
P2860
A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A signature in HIV-1 envelope ...... pe processing and infectivity.
@ast
A signature in HIV-1 envelope ...... pe processing and infectivity.
@en
A signature in HIV-1 envelope ...... pe processing and infectivity.
@nl
type
label
A signature in HIV-1 envelope ...... pe processing and infectivity.
@ast
A signature in HIV-1 envelope ...... pe processing and infectivity.
@en
A signature in HIV-1 envelope ...... pe processing and infectivity.
@nl
prefLabel
A signature in HIV-1 envelope ...... pe processing and infectivity.
@ast
A signature in HIV-1 envelope ...... pe processing and infectivity.
@en
A signature in HIV-1 envelope ...... pe processing and infectivity.
@nl
P2093
P2860
P50
P1433
P1476
A signature in HIV-1 envelope ...... pe processing and infectivity.
@en
P2093
Ina Hellmann
Marcus Daniels
Mohammed Asmal
Norman L Letvin
Weimin Liu
P2860
P304
P356
10.1371/JOURNAL.PONE.0023673
P407
P50
P577
2011-08-18T00:00:00Z